



AGENIX LIMITED

爱健克斯有限公司

(ASX: AGX)

ABN 58 009 213 754
465 Auburn Road,
Hawthorn, Vic, 3123
Australia
www.agenix.com

ASX MEDIA RELEASE

30 December 2010

Agenix Limited Securities Trading Policy

Agenix Limited (ASX: AGX) attaches the Agenix Limited Securities Trading Policy, in anticipation of, and compliance with, Listing Rule 12.9 when it comes into effect on 1 January 2011.

About Agenix Limited

Agenix is a publicly listed, Australian based international biotechnology company with a wholly owned subsidiary in China. The company has two core businesses:

- In **Innovative Biopharmaceuticals**, Agenix has 'in principal' rights to clinically develop a pipeline of innovative and proprietary Hepatitis B therapies for commercialisation in China. Through its wholly owned subsidiary, Agenix Biopharmaceutical (Shanghai), established in 2007, the company has established a collaboration with the Institute of Medicinal Biotechnology (**IMB**) of the Chinese Academy of Medical Sciences in Beijing to develop and commercialise AGX-1009, a next-generation, patented prodrug analog of an existing compound for the treatment of chronic HBV in China.
- In **Medical Diagnostics**, the company's lead indicator is a patented monoclonal antibody diagnostic called ThromboView® that, uniquely, detects live blood clots (DVT and PE) in the human body. ThromboView® has successfully completed two FDA Phase II human clinical trials in the United States. The company is positioning ThromboView® as an innovative diagnostic (a 'theranostic') to support the use of Novel Oral Anti-Coagulants and is seeking a development partner in China to commercialise the indicator.

Agenix has been listed on the Australian Securities Exchange (ASX: AGX) since 1987. Agenix is active in China, and seeking to establish commercial partnerships in the rest of the world. For additional information on Agenix Limited, please visit the company's website at <http://www.agenix.com>

Yours faithfully,

Nicholas Weston

Executive Chairman

Enclosures: Securities Trading Policy

CONTACT: Company Secretary Jeffrey Luckins:
+61 3 9822 8686 or email jluckins@agenix.com



AGENIX LIMITED

爱健克斯有限公司

(ASX: AGX)

ABN 58 009 213 754

**465 Auburn Road,
Hawthorn East, Vic, 3123
Australia**

www.agenix.com

AGENIX LIMITED

SECURITIES TRADING POLICY

1. Background

Agenix Limited (**Agenix/the Company**) has the following Securities Trading Policy to regulate dealings in shares and other securities issued by Agenix (**Dealings**). The Agenix Securities Trading Policy covers dealings by directors and employees of Agenix Limited, and directors and key management personnel of each of the Company's wholly owned subsidiaries (**Restricted Persons**).

To preserve the reputation and integrity of Agenix, when people associated with Agenix deal in the Company's securities, those dealings must not only be fair, but be seen to be fair. When Restricted Persons deal in the Company's securities they must be sure that it will not reflect improperly on them or upon Agenix.

The rationale for the Policy is to ensure that Restricted Persons are aware of the legal restrictions on trading Agenix securities while a person is in possession of unpublished price-sensitive information concerning the Company, and to impose certain closed periods during which, unless an exception applies, trading is prohibited.

2. Standards

All Restricted Persons should ensure that all transactions in Agenix shares or other securities which may be issued from time to time by the Company (**Agenix shares**) comply with:

- (a) the Corporations Act 2001 and Regulations (including, without limitation, the insider trading provisions); and
- (b) the ASX Limited Listing Rules (including, without limitation, the continuous disclosure requirements in Listing Rule 3.1 and the disclosure of the director's interests in accordance with Listing Rule 3.19A).

AGENIX LIMITED SECURITIES TRADING POLICY

3. Inside information

Information which is not generally available and information which a reasonable person would expect to have a material effect on the price or value of the particular financial products in question is known as **Inside Information**. The insider trading provisions of the Corporations Act (**Insider Trading Provisions**) operate to prohibit a 'person' (the definition of which includes a company) in possession of Inside Information in relation to financial products (including shares) from:

- (a) applying for, acquiring or disposing of those financial products (or entering into an agreement to do so) (**the trading offence**);
- (b) procuring another person to do any of the things set out in paragraph 2(a). A person will be taken to have procured another if that person incites, induces, or encourages or causes an act or omission by another person. (**the procuring offence**); and
- (c) in some cases where the financial products are able to be traded on a financial market, merely communicating the information.

4. Restrictions on trading and dealing

4.1. General restrictions

Restricted Persons:

- (a) must not engage in short term trading of any Agenix shares. An example of this would be to buy Agenix shares with an intention to sell the Company's shares within a 12 month period from the date of purchase; and
- (b) must not, despite anything to the contrary in this Policy, trade in any Agenix shares while that person is in possession of Inside Information.

4.2. Specific restrictions

Restricted Persons who hold Agenix shares under an incentive plan offered by Agenix from time to time, must not, without the prior consent in writing of Agenix, sell, create a security interest in, or otherwise dispose or deal with their Agenix shares or any of their interests in any of those Agenix shares.

5. Closed periods for trading

Subject to paragraph 6 below, Restricted Persons must not trade in Agenix shares during the following periods (**Closed Periods**):

- (a) 1 January up to and including the day on which Agenix's half year results are released; and

AGENIX LIMITED SECURITIES TRADING POLICY

- (b) 1 July up to and including the day on which Agenix's full year results are released.

6. Exemptions

6.1. Excluded trading

A Restricted Person may trade in Agenix shares during a closed period if that trading falls within one of the following categories: (**Excluded Trading**):

- (a) transfers of Agenix shares already held from a Restricted Person's own name into a superannuation fund to which the Restricted Person is a beneficiary;
- (b) an investment in, or trading in units of, a fund or other scheme (other than a scheme only investing in Agenix shares) where the assets of the fund or other scheme are invested at the discretion of a third party;
- (c) undertakings to accept, or the acceptance of, a takeover offer;
- (d) trading under an offer or invitation made to all or most of Agenix's members such as, a rights issue, a security purchase plan, a dividend or distribution reinvestment plan or an equal access buy-back, where the plan that determines the timing and structure of the offer has been approved by the Board;
- (e) a disposal of Agenix shares that is the result of a secured lender exercising their rights, for example, under a margin lending arrangement;
- (f) trading under any Agenix employee incentive scheme in accordance with the rules of a Board approved Incentive Plan; or
- (g) issue or exercise of rights and options (or each of them) granted under the Agenix Director and Executive Incentive Plan or its predecessors (including, without limitation, trading in shares to fund any attendant taxation consequences of the exercise of options). However, this Policy does apply in respect of the trading in any shares issued as a consequence of the exercise of incentive options.

6.2. Trading with consent

A Restricted Person may trade in Agenix shares during a closed period if that person obtains written consent to do so in accordance with paragraph 6.3.

6.3. Procedure for obtaining written consent to trade

- (a) A Restricted Person who wishes to trade in Agenix shares during a closed period (**Applicant**) must obtain the prior written consent of:
 - i. the Executive Chairman; or

AGENIX LIMITED SECURITIES TRADING POLICY

- ii. where the Executive Chairman is the Applicant, the Non-Executive Directors of the Board of Agenix (collectively, the **Decision Maker/s**).
- (b) As part of such application, an Applicant must give the Decision Maker/s an undertaking that the Applicant complies with paragraph 4.1(a) of the Policy;
- (c) The Decision Maker/s may only provide written permission to trade in Agenix shares where:
 - i. the Restricted Person is in severe financial hardship or other exceptional circumstances exist; and
 - ii. the Decision Maker/s are satisfied that there is no inside information which has not been disclosed to ASX Limited.
- (d) The following are examples of situations of severe financial hardship or other exceptional circumstances which the Decision Maker/s may consider sufficient to warrant approval under this paragraph 6:
 - i. “severe financial hardship” could include (but is not limited to) the Applicant having a pressing financial commitment that cannot be satisfied otherwise than by selling the relevant Agenix shares; and
 - ii. “exceptional circumstances” could include (but is not limited to) where the Applicant is required by a court order, or there are court enforceable undertakings, for example, in a bona fide family settlement, to transfer or sell Agenix shares or there is some other overriding legal or regulatory requirement for the Applicant to do so.
- (e) An Applicant seeking clearance to trade must satisfy the Decision Maker/s that they are in severe financial hardship or that their circumstances are otherwise exceptional and that the proposed sale or disposal of the relevant Agenix shares is the only reasonable course of action available.
- (f) Determination as to whether the Applicant is in severe financial hardship or whether a particular set of circumstances exist may only be made by the Decision Maker/s.
- (g) Any permission provided under this paragraph 6 must be obtained by the Applicant not less than 2 business days before the proposed trading.

7. Policy responsibility

Each Restricted Person is responsible for adhering to the Company’s standard for trading in Agenix shares.

The Company Secretary has responsibility for enforcing the Policy.

AGENIX LIMITED SECURITIES TRADING POLICY

8. Compliance with Policy and the Corporations Act

The requirements imposed by this Policy are separate from, and additional to, the legal prohibitions in the Corporations Act .

Directors, officers and employees should be aware that they can be charged with criminal offences under the rules and regulations associated with the prevention of insider trading. Accordingly, it is the responsibility of each director, officer and employee to ensure that they abide by this Policy and the law. The Corporations Act also provides for a range of other prohibitions and penalties relating to dealing with shares including market manipulation, false trading, market rigging and misleading and deceptive conduct, none of which are necessarily covered by this Policy by apply at law in any event.

Failure to comply with this Policy is considered cause for termination of employment.

- end -